That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found that adding Mineralys' aldosterone synthase inhibitor lorundrostat to the ...

Perspectives from Keith Churchwell, MD, FAHA Keith C. Ferdinand, MD CHICAGO — The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well ...

Mineralys Therapeutics, Inc. announced that it will present data from its Phase 2 Advance-HTN trial on lorundrostat, a novel aldosterone synthase inhibitor for treating uncontrolled and resistant ...

Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other ...

The $26-per-share upfront deal focuses on baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) in clinical testing for treatment-resistant hypertension and chronic kidney disease.

Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of ...

The study is evaluating the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, in treating ...

Oral lorundrostat targets dysregulated mineralcorticoid aldosterone as a selective aldosterone synthase inhibitor. Mineralys estimated there to be about 15- to 20-million patients with uncontrolled ...

Its lead product candidate, lorundrostat, is an aldosterone synthase inhibitor designed to treat hypertension by targeting aldosterone-driven high blood pressure. The company aims to provide a ...